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Introduction
Community-acquired pneumonia (CAP) remains one of the major causes of morbidity and mortality worldwide, despite the advances in diagnostic methods and treatment and it is the leading cause of severe sepsis [1, 2] . Recent studies have been focused on the role that inflammation plays in the pathogenesis of this disease. Inflammation is part of the host's immune response against infection and if uncontrolled, it can have deleterious consequences for the host [3, 4] . Several cytokines have been identified in immunopathogenesis of CAP, but most studies that analyzed them, have reported conflicting results and were limited to a single serum determination. IL-1β, IL-6, IL-8 and TNF-α as pro-inflammatory, and IL-10 as anti-inflammatory cytokines, have been the most studied in CAP [1, 5] . IL-4 is another anti-inflammatory cytokine that has been postulated to have important role in allergic diseases, but also in the immune response against Mycoplasma pneumoniae [6, 7] . IL-17A has recently been involved in the immune response during CAP, playing an important role in acute inflammation induced by infectious agents in the airway. [7, 8] . This study aimed to investigate inflammation in CAP, by testing serum levels of IL-1β, TNF-α and IL-6 as pro-inflammatory cytokines, IL-10 and IL-4 as anti-inflammatory cytokines and the relationship between them and IL-17A. We studied the interleukin dynamics on admission and on day 4 of hospitalization and their predictive value regarding adverse outcomes.
Materials and methods
Patients and study design A prospective study was carried out from December 2015 to February 2017 in the Teaching Hospital of Infectious Diseases Cluj-Napoca, Romania and it included adult patients with community-acquired pneumonia defined according to the IDSA [9] . The study protocol was approved by the medical ethics committee of both the Hospital and "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Romania. A written informed consent was obtained from the patients or closest relatives in each case. Exclusion criteria were represented by: age under 18 years old, pregnancy, HIV infection, active tuberculosis, known malignancies and autoimmune diseases requiring immunosuppressive drugs. Patients were followed-up 90 days after discharge. Patients were enrolled in the study group within 24 hours of hospital admission. We recorded demographical data, clinical data, length of stay (LOS) in the hospital, various scores for pneumonia severity [10, 11] , usage of antibiotics prior to hospital admission, presence of complications such as sepsis, according to ACCP/SCCM criteria [12] , acute respiratory failure and pleurisy, adverse outcomes during follow-up (relapses or death). Venous blood samples for cytokine measurements were collected from each patient within the first 24 hours following admission, between 7 and 9 AM, and then again on day 4 of hospitalization. After centrifugation, the serum from patients was split into 2-4 cryotubes and stored at -70⁰ C until it was analyzed. In order to study the relationship between CAP and inflammation, we analyzed serum levels of cytokines using commercially available enzyme immunoassay technique (ELISA) (IL-1β, IL-4, IL-6, IL-10 and IL-17A using BioVendor®Re-search and Diagnostic products, USA; TNF-α using Hycult® biotech assay,USA). The detection limits were 0.3 pg/ml for IL-1β, 1.3 pg/ml We questioned if any interleukin value on day 1 (prior to antibiotic treatment) was predictive for adverse outcomes and the results were that only IL-6 had significant contribution (p=0.043, cut-off= 28.46 pg/mL), discriminating between adverse outcomes and favourable outcomes. 
Discussion
Epidemiological studies tried to find the impact of age and gender on CAP caused by different [1, 7] . Bacci et al found an association between TNF-α and gender, and IL-1 was correlated with age, but the sample size was small, with only 26 subjects [16] . Previous studies found that systemic levels of IL-1β, IL-6 and TNF-α are usually elevated in patients with CAP, but they analyzed cytokines serum levels by only one determination [3, 17] . G. Antunes et al showed a temporal pattern of these cytokines, with the serum levels declined rapidly over 5 days and postulated that pro-inflammatory cytokines were associated with poor prognosis in CAP [1] . M. Holub et al found that elevated levels of IL-6 and TNF-α decreased within 3 days after admission, to levels similar to that of healthy subjects [18] . Similar with these findings, we found a decrease in the serum levels of IL-1β, IL-6 and TNF-α within 4 days of antibiotherapy, acting as acute phase proteins. One explanation is the start of antibiotic treatment, and, in some cases, corticotherapy, which reduces the inflammatory response. In our study, similar to others [16] , we found correlations between pro-inflammatory cytokines IL-1β, IL-6 and TNF-α. The statistical model we used showed that high serum levels of IL-6 on day 1 associated with adverse outcomes consisted in relapses or death after 90 days of discharge. Similarly, Bacci M et al demonstrated that serum levels of IL-6 and TNF-α were correlated with worse outcomes [16] . There are several studies postulating that IL-6 is a marker of severity in CAP both in adults and children [7, 19, 20, 21] . IL-4 has been best studied in the pathogenesis of asthma [22] . A recent study by M.J Giuffrida et al showed that there was no difference in serum levels of IL-4 and other cytokines studied, in asthmatic and non-asthmatic patients with bacterial, viral or mixed lung infection [23] . However, there are limited data regarding systemic levels of IL-4 in adults with CAP, most studies being concentrated on paediatric population and the role in the immune response against Mycoplasma pneumonia [6, 24, 25] . M.S Paats et al found that levels of IL-4 and IL-17A could not be detected in serum nor in bronchoalveolar lavage fluid (BAL) of the patients with CAP [7] . Unlike them, we found detectable serum levels of IL-4 on admission in almost all of our patients, with 2 exceptions, and in 27 cases their levels increased within 4 days of treatment. From the rest, 2 had relapses, and the others had only slightly decreased in their IL-4 values. Out of 38 patients, only 2 were known to have asthma, controlled at the time of hospital admission. Our results reinforce the idea that the immune response during bacterial infection is probably similar to the early phases of the immune response in asthma [23] . We also found a positive correlation between IL-4, IL-6, IL-17A and IL-10 that can be explained by a common origin, meaning T-helper cells. [26] Regarding IL-10, we found an opposite behaviour to IL-4, paradoxically, the decline of values from day 1 to day 4, acting as an acute phase biomarker, consistent with previous reports [1, 3, 5, 7] . Similar to these studies, we found a correlation between IL-6 and IL-10. A possible explanation for the different behaviour of IL-10 compared to IL-4 could be that they have different dynamics. Also, at the time of admission, patients were in different stages of pneumonia, a possible explanation for their differences.
It has been proven that IL-17A has a protective role in host defense against airway pathogens in mice, but it is also involved in the local and systemic immune response in human pneumonia [27, 28] . In a recent study, F. Higa et al postulated that this cytokine might play a role in legionnaire disease [29] . M.S. Paats et al studied the systemic and local involvement of IL-17A in CAP, among other cytokines, but its levels in both BAL fluid and serum of patients or healthy controls were not found [7] . In our study, we found detectable levels of IL-17A in 38 patients, behaving mostly as pro-inflammatory cytokines, with decreasing levels from day 1 to day 4, although it did not reach statistical significance. Also we found a correlation between IL-17A, IL-6 and surprisingly IL-10, reinforcing the pro-inflammatory effect.
In this study we found a relationship between IL-6, IL-1β, IL-4 and IL-10 and adverse outcomes (relapses and mortality). However, we have not found a correlation between cytokine levels and PSI risk class, partly because of the small number of subjects studied and also because we evaluated the severity scores only at admission. Endeman et al have also found no association between cytokine levels and this severity score [5] . Kellum et al described the systemic cytokine response to infection and severe sepsis in a large cohort of patients with CAP, suggesting that individuals with high serum levels of both pro and anti-inflammatory cytokines had an increased risk of severe sepsis and death [30] . The present study has some limitations that should be considered. Firstly, the number of patients included was small, although we obtained relevant results for CAP. Secondly, we searched for systemic response only, not local immune response. Ideally, both responses should have been studied. However, many of the prognostic scores in CAP relate to the systemic rather than pulmonary effects of the biomarkers [31] . Another limitation is the prior prescription of antibiotics in 20% of our patients, which has certainly modulated the inflammatory response and cytokine expression. Also, the etiology was established in only 10 cases, which made it impossible to carry out statistical tests demonstrating the relationship between cytokines and etiology.
Conclusion
In conclusion, based on a comprehensive analysis of the systemic cytokine response in CAP, we have proved that IL-6 is a predictive marker for adverse outcomes and should be routinely analyzed at admission. IL-17A and IL-10 behave like pro-inflammatory cytokines, underlining the fact that the dynamic of these cytokines depends on several factors, such as the time of admission and prior usage of antibiotics. Although the number of the patients was small, we demonstrated a model in which all the studied combined interleukins had an impact on adverse outcomes. 
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